Key result
MTMR4 variants protect ~77% of asymptomatic KCNQ1-Y111C carriers against LQTS by reducing Nedd4L-mediated channel degradation.
Why the study?
In LQTS patients, modifier genes modulate arrhythmic risk and can improve risk stratification, but their discovery and elucidation of their mechanism of action represent a challenge.
Does correction of MTMR4 SNVs unmask the LQTS phenotype in iPSC-CMs from asymptomatic KCNQ1-Y111C mutation carriers?
Does correction of MTMR4 SNVs unmask the LQTS phenotype in iPSC-CMs from asymptomatic KCNQ1-Y111C mutation carriers?
MTMR4 SNVs act as protective modifier genes in LQTS by interfering with Nedd4L activation, reducing ion channel degradation and arrhythmogenic risk.
MTMR4 variants may modify LQTS penetrance in KCNQ1 carriers; leaves open therapeutic targeting pending human validation.
AIMS: In long QT syndrome (LQTS) patients, modifier genes modulate the arrhythmic risk associated with a disease-causing mutation. Their recognition can improve risk stratification and clinical management, but their discovery represents a challenge. We tested whether a cellular-driven approach could help to identify new modifier genes and especially their mechanism of action. METHODS AND RESULTS: We generated human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) from two patients carrying the same KCNQ1-Y111C mutation, but presenting opposite clinical phenotypes. We showed that the phenotype of the iPSC-CMs derived from the symptomatic patient is due to impaired trafficking and increased degradation of the mutant KCNQ1 and wild-type human ether-a-go-go-related gene. In the iPSC-CMs of the asymptomatic (AS) patient, the activity of an E3 ubiquitin-protein ligase (Nedd4L) involved in channel protein degradation was reduced and resulted in a decreased arrhythmogenic substrate. Two single-nucleotide variants (SNVs) on the Myotubularin-related protein 4 (MTMR4) gene, an interactor of Nedd4L, were identified by whole-exome sequencing as potential contributors to decreased Nedd4L activity. Correction of these SNVs by CRISPR/Cas9 unmasked the LQTS phenotype in AS cells. Importantly, the same MTMR4 variants were present in 77% of AS Y111C mutation carriers of a separate cohort. Thus, genetically mediated interference with Nedd4L activation seems associated with protective effects. CONCLUSION: Our finding represents the first demonstration of the cellular mechanism of action of a protective modifier gene in LQTS. It provides new clues for advanced risk stratification and paves the way for the design of new therapies targeting this specific molecular pathway.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) studied Long QT syndrome. MTMR4 single-nucleotide variants vs. Symptomatic KCNQ1-Y111C mutation carriers was evaluated on Presence of MTMR4 variants in asymptomatic Y111C mutation carriers. MTMR4 single-nucleotide variants were present in 77% of asymptomatic KCNQ1-Y111C mutation carriers and protected against the long QT syndrome phenotype by reducing Nedd4L-mediated channel degradation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: